[HTML][HTML] Long-term systemic expression of a novel PD-1 blocking nanobody from an AAV vector provides antitumor activity without toxicity
N Silva-Pilipich, E Martisova, MC Ballesteros-Briones… - Biomedicines, 2020 - mdpi.com
Immune checkpoint blockade using monoclonal antibodies (mAbs) able to block
programmed death-1 (PD-1)/PD-L1 axis represents a promising treatment for cancer …
programmed death-1 (PD-1)/PD-L1 axis represents a promising treatment for cancer …
[HTML][HTML] Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity
N Silva-Pilipich, E Martisova… - …, 2020 - ncbi.nlm.nih.gov
Immune checkpoint blockade using monoclonal antibodies (mAbs) able to block
programmed death-1 (PD-1)/PD-L1 axis represents a promising treatment for cancer …
programmed death-1 (PD-1)/PD-L1 axis represents a promising treatment for cancer …
Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity
N Silva-Pilipich, E Martisova… - …, 2020 - pubmed.ncbi.nlm.nih.gov
Immune checkpoint blockade using monoclonal antibodies (mAbs) able to block
programmed death-1 (PD-1)/PD-L1 axis represents a promising treatment for cancer …
programmed death-1 (PD-1)/PD-L1 axis represents a promising treatment for cancer …
Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity.
N Silva-Pilipich, E Martisova… - Biomedicines, 2020 - europepmc.org
Immune checkpoint blockade using monoclonal antibodies (mAbs) able to block
programmed death-1 (PD-1)/PD-L1 axis represents a promising treatment for cancer …
programmed death-1 (PD-1)/PD-L1 axis represents a promising treatment for cancer …
Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity
NR Silva-Pilipich, E Martisova, MC Ballesteros-Briones… - 2020 - dadun.unav.edu
Immune checkpoint blockade using monoclonal antibodies (mAbs) able to block
programmed death-1 (PD-1)/PD-L1 axis represents a promising treatment for cancer …
programmed death-1 (PD-1)/PD-L1 axis represents a promising treatment for cancer …
[PDF][PDF] Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity
N Silva-Pilipich, E Martisova, MC Ballesteros-Briones… - pdfs.semanticscholar.org
Immune checkpoint blockade using monoclonal antibodies (mAbs) able to block
programmed death-1 (PD-1)/PD-L1 axis represents a promising treatment for cancer …
programmed death-1 (PD-1)/PD-L1 axis represents a promising treatment for cancer …
[引用][C] Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity
N Silva-Pilipich, E Martisova… - Biomedicines …, 2020 - jglobal.jst.go.jp
Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector
Provides Antitumor Activity without Toxicity | Article Information | J-GLOBAL Art J-GLOBAL ID:202102268821872737 …
Provides Antitumor Activity without Toxicity | Article Information | J-GLOBAL Art J-GLOBAL ID:202102268821872737 …
Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity.
N Silva-Pilipich, E Martisova… - …, 2020 - search.ebscohost.com
Immune checkpoint blockade using monoclonal antibodies (mAbs) able to block
programmed death-1 (PD-1)/PD-L1 axis represents a promising treatment for cancer …
programmed death-1 (PD-1)/PD-L1 axis represents a promising treatment for cancer …
[PDF][PDF] Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity
N Silva-Pilipich, E Martisova, MC Ballesteros-Briones… - riquim.fq.edu.uy
Immune checkpoint blockade using monoclonal antibodies (mAbs) able to block
programmed death-1 (PD-1)/PD-L1 axis represents a promising treatment for cancer …
programmed death-1 (PD-1)/PD-L1 axis represents a promising treatment for cancer …
Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity
N Silva-Pilipich, E Martisova, MC Ballesteros-Briones… - search.proquest.com
Immune checkpoint blockade using monoclonal antibodies (mAbs) able to block
programmed death-1 (PD-1)/PD-L1 axis represents a promising treatment for cancer …
programmed death-1 (PD-1)/PD-L1 axis represents a promising treatment for cancer …